Several large epidemiological studies revealed findings that the clinical use of β2AR agonists (primarily for patients with asthma) was associated with a decreased incidence of PD compared to the general population and that the use of a β2AR antagonist (primarily for the treatment of hypertension) led to an increased incidence. The gene discussed is ADRB2; the disease is asthma.